Orchard Healthcare Research Inc. | Skokie, IL

Research site

Site insights

Top conditions

Top treatments


Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 25 total trials

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Or...

Active, not recruiting
Part 2:B-cell Malignancies
Part 1:r/r B-cell Malignancies
Drug: Orelabrutinib (ICP-022)

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Advanced or Metastatic Breast Cancer
Drug: Everolimus
Drug: Fulvestrant
Locations recently updated

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R ver...

Myelodysplastic Syndromes
Biological: Epoetin Alfa
Biological: Luspatercept

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is a...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanc...

Active, not recruiting
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Drug: Sitravatinib
Drug: Docetaxel
Locations recently updated

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (sac-TMT; MK-2870) in combination with p...

Triple-Negative Breast Cancer
Biological: sac-TMT
Biological: Pembrolizumab
Locations recently updated

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at...

Begins enrollment this month
Locally Advanced Breast Cancer
Triple Negative Breast Cancer
Drug: BNT327 Dose Level 1 (DL2)
Drug: Antimetabolite

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadju...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or br...

Chemotherapy-induced Thrombocytopenia
Drug: Placebo
Drug: Romiplostim

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizu...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Sacituzumab Govitecan-hziy (SG)
Drug: Pembrolizumab

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are R...

Myelodysplastic Syndromes
Drug: Azacitidine
Drug: Tamibarotene

Trial sponsors

Bristol-Myers Squibb (BMS) logo
Gilead Sciences logo
BioNTech logo
Celgene logo
Merck Sharp & Dohme (MSD) logo
Pfizer logo
Amgen logo
Celldex Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems